Corcept Therapeutics is a pharmaceutical firm engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. The company s lead product candidate, Corlux, is in clinical trials for the treatment of the psychotic features of psychotic major depression. PMD is a disorder that affects nearly three million people in the United States annually. The U.S. Food and Drug Administration has granted fast-track status to Corcept Therapeutics program. The company is headquartered in Menlo Park, Calif.